SOST and osteogenesis imperfecta: To this aim, an anti-sclerostin antibody that inhibits the negative regulator of the WNT pathway in osteoblasts and was recently approved for osteoporosis treatment by the EMA and FDA was used in OI animal models where it improved bone strength and microarchitecture, and reduced axial and long bone fractures (23–25).